Literature DB >> 24792354

LMO2 induces T-cell leukemia with epigenetic deregulation of CD4.

Susan M Cleveland1, Charnise Goodings1, Rati M Tripathi1, Natalina Elliott1, Mary Ann Thompson2, Yan Guo3, Yu Shyr3, Utpal P Davé4.   

Abstract

In this study, we present a remarkable clonal cell line, 32080, derived from a CD2-Lmo2- transgenic T-cell leukemia with differentiation arrest at the transition from the intermediate single positive to double positive stages of T-cell development. We observed that 32080 cells had a striking variegated pattern in CD4 expression. There was cell-to-cell variability, with some cells expressing no CD4 and others expressing high CD4. The two populations were isogenic and yet differed in their rates of apoptosis and sensitivity to glucocorticoid. We sorted the 32080 line for CD4-positive or CD4-negative cells and observed them in culture. After 1 week, both sorted populations showed variegated CD4 expression, like the parental line, showing that the two populations could interconvert. We determined that cell replication was necessary to transit from CD4(+) to CD4(-) and CD4(-) to CD4(+). Lmo2 knockdown decreased CD4 expression, while inhibition of intracellular NOTCH1 or histone deacetylase activity induced CD4 expression. Enforced expression of RUNX1 repressed CD4 expression. We analyzed the CD4 locus by Histone 3 chromatin immunoprecipitation and found silencing marks in the CD4(-) cells and activating marks in the CD4(+) population. The 32080 cell line is a striking model of intermediate single positive to double positive T-cell plasticity and invokes a novel mechanism for LMO2's oncogenic functions.
Copyright © 2014 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792354      PMCID: PMC4241760          DOI: 10.1016/j.exphem.2014.04.010

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  57 in total

1.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.

Authors:  Annette Deichmann; Salima Hacein-Bey-Abina; Manfred Schmidt; Alexandrine Garrigue; Martijn H Brugman; Jingqiong Hu; Hanno Glimm; Gabor Gyapay; Bernard Prum; Christopher C Fraser; Nicolas Fischer; Kerstin Schwarzwaelder; Maria-Luise Siegler; Dick de Ridder; Karin Pike-Overzet; Steven J Howe; Adrian J Thrasher; Gerard Wagemaker; Ulrich Abel; Frank J T Staal; Eric Delabesse; Jean-Luc Villeval; Bruce Aronow; Christophe Hue; Claudia Prinz; Manuela Wissler; Chuck Klanke; Jean Weissenbach; Ian Alexander; Alain Fischer; Christof von Kalle; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  Runx1 binds positive transcription elongation factor b and represses transcriptional elongation by RNA polymerase II: possible mechanism of CD4 silencing.

Authors:  Huimin Jiang; Fan Zhang; Takeshi Kurosu; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

Review 3.  From stem cell to T cell: one route or many?

Authors:  Avinash Bhandoola; Arivazhagan Sambandam
Journal:  Nat Rev Immunol       Date:  2006-02       Impact factor: 53.106

4.  Groucho-dependent and -independent repression activities of Runt domain proteins.

Authors:  B D Aronson; A L Fisher; K Blechman; M Caudy; J P Gergen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

5.  Tie2Cre-mediated gene ablation defines the stem-cell leukemia gene (SCL/tal1)-dependent window during hematopoietic stem-cell development.

Authors:  Thorsten M Schlaeger; Hanna K A Mikkola; Christos Gekas; Hildur B Helgadottir; Stuart H Orkin
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

6.  RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription.

Authors:  E Reed-Inderbitzin; I Moreno-Miralles; S K Vanden-Eynden; J Xie; B Lutterbach; K L Durst-Goodwin; K S Luce; B J Irvin; M L Cleary; S J Brandt; S W Hiebert
Journal:  Oncogene       Date:  2006-05-01       Impact factor: 9.867

7.  The transcription factor Zbtb7b promotes CD4 expression by antagonizing Runx-mediated activation of the CD4 silencer.

Authors:  Kathryn F Wildt; Guangping Sun; Baerbel Grueter; Maria Fischer; Monica Zamisch; Marc Ehlers; Rémy Bosselut
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

8.  Antagonistic interactions between Ikaros and the chromatin remodeler Mi-2beta determine silencer activity and Cd4 gene expression.

Authors:  Taku Naito; Pablo Gómez-Del Arco; Christine J Williams; Katia Georgopoulos
Journal:  Immunity       Date:  2007-11-01       Impact factor: 31.745

9.  Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL.

Authors:  R A Shivdasani; E L Mayer; S H Orkin
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

10.  Novel binding partners of Ldb1 are required for haematopoietic development.

Authors:  Natalia Meier; Sanja Krpic; Patrick Rodriguez; John Strouboulis; Maria Monti; Jeroen Krijgsveld; Martin Gering; Roger Patient; Arnd Hostert; Frank Grosveld
Journal:  Development       Date:  2006-11-15       Impact factor: 6.868

View more
  6 in total

1.  PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.

Authors:  Evgeni Efimenko; Utpal P Davé; Irina V Lebedeva; Yao Shen; Maria J Sanchez-Quintero; Daniel Diolaiti; Andrew Kung; Brian J Lannutti; Jianchung Chen; Ronald Realubit; Zoya Niatsetskaya; Vadim Ten; Charles Karan; Xi Chen; Andrea Califano; Thomas G Diacovo
Journal:  Mol Cancer Ther       Date:  2017-07-17       Impact factor: 6.261

2.  Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.

Authors:  Charnise Goodings; Rati Tripathi; Susan M Cleveland; Natalina Elliott; Yan Guo; Yu Shyr; Utpal P Davé
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

3.  LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.

Authors:  Justin H Layer; Catherine E Alford; W Hayes McDonald; Utpal P Davé
Journal:  Mol Cell Biol       Date:  2015-11-23       Impact factor: 4.272

4.  DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias.

Authors:  Liubin Yang; Benjamin Rodriguez; Allison Mayle; Hyun Jung Park; Xueqiu Lin; Min Luo; Mira Jeong; Choladda V Curry; Sang-Bae Kim; David Ruau; Xiaotian Zhang; Ting Zhou; Michael Zhou; Vivienne I Rebel; Grant A Challen; Berthold Gottgens; Ju-Seog Lee; Rachel Rau; Wei Li; Margaret A Goodell
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

Review 5.  ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?

Authors:  Bieke Soen; Niels Vandamme; Geert Berx; Jürg Schwaller; Pieter Van Vlierberghe; Steven Goossens
Journal:  Hemasphere       Date:  2018-05-11

6.  Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies.

Authors:  Allison Greenplate; Kai Wang; Rati M Tripathi; Norma Palma; Siraj M Ali; Phil J Stephens; Vincent A Miller; Yu Shyr; Yan Guo; Nishitha M Reddy; Lina Kozhaya; Derya Unutmaz; Xueyan Chen; Jonathan M Irish; Utpal P Davé
Journal:  JCO Precis Oncol       Date:  2018-02-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.